CINGAL Phase III Data Demonstrates Efficacy and Safety to Treat Knee OA Pain

Phase III study results demonstrated that Anika Therapeutics' CINGAL® hyaluronic acid (HA)/corticosteroid viscosupplement provided superior immediate and short term pain relief after injection vs. HA alone, and superior relief from OA-related pain, stiffness and function through 26 weeks vs. saline.

CINGAL remains under FDA regulatory review...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us